Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Obecabtagene autoleucel |
Synonyms | |
Therapy Description |
Obecabtagene autoleucel comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially decrease tumor growth (J Clin Oncol 41, no. 16_suppl (June 01, 2023) 7000). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Obecabtagene autoleucel | Obe-cel|AUTO1|AUTO-1|AUTO 1 | Obecabtagene autoleucel comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially decrease tumor growth (J Clin Oncol 41, no. 16_suppl (June 01, 2023) 7000). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | GBR | 0 |